nk 611 has been researched along with Neoplasms in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| D'Incalci, M; De Fusco, M; Gentili, D; Reichert, S; Zucchetti, M | 1 |
| D'Incalci, M; De Fusco, M; Fröhlich, A; Reichert, S; Sessa, C; Zucchetti, M | 1 |
| Cavalli, F; D'Incalci, M; De Fusco, M; de Jong, J; Hanauske, A; Kaeser-Fröhlich, A; Pagani, O; Sessa, C; Zucchetti, M | 1 |
| Hanauske, AR; Kaeser-Fröhlich, A; Rassmann, I; Rastetter, J; Schilling, T; Schrödel, H; Zucchetti, M | 1 |
3 trial(s) available for nk 611 and Neoplasms
| Article | Year |
|---|---|
High-performance liquid chromatographic assay for the determination of the novel etoposide derivative dimethylaminoetoposide (NK611) and its metabolites in urine of cancer patients.
Topics: Administration, Oral; Antineoplastic Agents; Chromatography, High Pressure Liquid; Humans; Injections, Intravenous; Neoplasms; Podophyllotoxin; Quality Control; Spectrophotometry, Ultraviolet | 1995 |
Clinical and pharmacokinetic study of oral NK611, a new podophyllotoxin derivative.
Topics: Administration, Oral; Adrenal Gland Neoplasms; Adult; Aged; Antineoplastic Agents; Area Under Curve; Biological Availability; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Administration Schedule; Female; Humans; Injections, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasms; Neutropenia; Podophyllotoxin; Thrombocytopenia | 1996 |
Clinical and pharmacokinetic phase I trial of oral dimethylaminoetoposide (NK611) administered for 21 days every 35 days.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Cell Count; Drug Administration Schedule; Female; Humans; Leukopenia; Male; Middle Aged; Neoplasms; Neutropenia; Podophyllotoxin | 1996 |
1 other study(ies) available for nk 611 and Neoplasms
| Article | Year |
|---|---|
High-performance liquid chromatographic assay for the determination of the novel podophyllotoxin derivative dimethylaminoetoposide (NK611) in human plasma.
Topics: Antineoplastic Agents; Biological Availability; Chromatography, High Pressure Liquid; Humans; Metabolic Clearance Rate; Neoplasms; Podophyllotoxin; Quality Control; Sensitivity and Specificity | 1994 |